Vancomycin kills bacteria by blocking the construction of their cell walls. It does this by physically binding to a specific building block in the wall’s structure, preventing the wall from forming properly. Without an intact cell wall, the bacterium’s internal contents leak out and the cell dies. This makes vancomycin one of the most important antibiotics for treating serious infections caused by resistant bacteria like MRSA.
The Cell Wall Target
Bacterial cell walls are built from a rigid, mesh-like material called peptidoglycan. Think of it as a scaffold made of long sugar chains cross-linked together by short protein segments. The bacterium assembles this scaffold by connecting new building blocks to the growing wall, a process that requires enzymes to stitch the pieces together.
Vancomycin works by grabbing onto the end of one of those building blocks before it can be stitched into the wall. Specifically, it latches onto a two-part structure at the tip of each protein segment (called D-Ala-D-Ala in biochemistry). Five hydrogen bonds form between vancomycin’s rigid, cage-like core and this target, creating a tight grip that blocks the enzymes responsible for cross-linking the wall. With the cross-linking process stalled, the bacterium can’t maintain or grow its protective shell. The wall weakens, internal pressure causes the cell to burst, and the bacterium dies.
Why It Only Works on Certain Bacteria
Vancomycin is effective only against gram-positive bacteria. These include Staphylococcus aureus (including MRSA), Streptococcus species, and Enterococcus species. Gram-negative bacteria are naturally immune to vancomycin because they have an outer membrane surrounding their cell wall. Vancomycin is a large, bulky molecule that simply can’t pass through this outer barrier to reach the peptidoglycan underneath.
How Bacteria Develop Resistance
Some bacteria, particularly certain strains of Enterococcus (known as VRE, or vancomycin-resistant Enterococci), have evolved a clever workaround. Instead of building their cell wall with the normal D-Ala-D-Ala ending that vancomycin grips onto, they swap in a slightly different molecule at the tip of the building block.
The most common swap replaces one of the two components with a molecule called D-lactate. This change eliminates just one of the five hydrogen bonds vancomycin relies on, but that single lost bond reduces vancomycin’s binding strength by 1,000-fold. At that level, the drug is essentially useless. A less common version of resistance swaps in a molecule called D-serine instead, which creates a physical obstruction that reduces binding about 6-fold. This produces lower-level resistance, meaning vancomycin still has some activity but not enough to reliably treat the infection.
Two Routes, Two Different Jobs
Vancomycin is unusual in that it can be given intravenously or by mouth, but these two routes treat completely different infections. When given by IV, vancomycin travels through the bloodstream to reach infections in the heart, bones, blood, and other tissues. This is how it’s used for serious MRSA infections.
When taken by mouth, vancomycin stays almost entirely in the gut. In one study of 57 patients taking oral vancomycin, 98% had no detectable drug in their bloodstream at all. This near-zero absorption is actually the point: oral vancomycin is used specifically to treat Clostridioides difficile infections in the intestines, where high local concentrations of the drug can kill the bacteria directly without entering the rest of the body.
The Infusion Reaction
One well-known side effect of IV vancomycin is a flushing reaction that causes redness across the face, neck, and upper body. This happens because vancomycin triggers certain immune cells (mast cells and basophils) to release histamine, not through an allergic mechanism but through a direct chemical effect. It’s not a true allergy, and it’s largely preventable by controlling how fast the drug is infused. Current guidelines recommend infusing vancomycin no faster than 10 mg per minute. When the infusion rate stays below that threshold, the reaction is far less likely to occur.
How Doctors Track the Right Dose
Vancomycin has a relatively narrow sweet spot between an effective dose and one that risks kidney damage. Too little drug in the body and the infection won’t clear. Too much and the kidneys can suffer. For serious MRSA infections, guidelines from the Infectious Diseases Society of America recommend targeting a specific ratio of drug exposure over time relative to the bacteria’s susceptibility, aiming for a value between 400 and 600.
Older practice relied on checking a single blood level (called a trough) drawn just before the next dose. More recent evidence has shown that this approach tends to push doses higher than necessary, increasing kidney toxicity. The current recommended method uses multiple blood draws to estimate total drug exposure over a 24-hour period, which has been shown to reduce kidney injury rates without sacrificing effectiveness. If you’re receiving vancomycin in a hospital, you can expect periodic blood draws to make sure your levels stay in the target range.
Where Vancomycin Came From
Vancomycin originated from a soil sample collected in Borneo in 1952. A missionary sent the sample to a chemist at Eli Lilly, where researchers isolated a microorganism (now classified as Amycolatopsis orientalis) that produced a substance lethal to most gram-positive bacteria, including strains already resistant to penicillin. That substance became vancomycin, and it entered clinical use in the late 1950s. For decades it was considered a drug of last resort, reserved for the most resistant infections. Today, with MRSA widespread in hospitals and communities, it remains one of the most commonly used antibiotics for serious gram-positive infections.